1911 related articles for article (PubMed ID: 10699287)
1. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
Maeda H; Wu J; Sawa T; Matsumura Y; Hori K
J Control Release; 2000 Mar; 65(1-2):271-84. PubMed ID: 10699287
[TBL] [Abstract][Full Text] [Related]
2. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
Fang J; Sawa T; Maeda H
Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
[TBL] [Abstract][Full Text] [Related]
3. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.
Fang J; Islam W; Maeda H
Adv Drug Deliv Rev; 2020; 157():142-160. PubMed ID: 32553783
[TBL] [Abstract][Full Text] [Related]
4. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
5. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting.
Maeda H
Proc Jpn Acad Ser B Phys Biol Sci; 2012; 88(3):53-71. PubMed ID: 22450535
[TBL] [Abstract][Full Text] [Related]
6. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.
Maeda H; Fang J; Inutsuka T; Kitamoto Y
Int Immunopharmacol; 2003 Mar; 3(3):319-28. PubMed ID: 12639809
[TBL] [Abstract][Full Text] [Related]
7. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
Nakamura H; Fang J; Maeda H
Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
[TBL] [Abstract][Full Text] [Related]
8. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
9. Polymer therapeutics and the EPR effect.
Maeda H
J Drug Target; 2017; 25(9-10):781-785. PubMed ID: 28988499
[TBL] [Abstract][Full Text] [Related]
10. The link between infection and cancer: tumor vasculature, free radicals, and drug delivery to tumors via the EPR effect.
Maeda H
Cancer Sci; 2013 Jul; 104(7):779-89. PubMed ID: 23495730
[TBL] [Abstract][Full Text] [Related]
11. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.
Maeda H; Nakamura H; Fang J
Adv Drug Deliv Rev; 2013 Jan; 65(1):71-9. PubMed ID: 23088862
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.
Maeda H; Sawa T; Konno T
J Control Release; 2001 Jul; 74(1-3):47-61. PubMed ID: 11489482
[TBL] [Abstract][Full Text] [Related]
13. Macromolecular therapeutics in cancer treatment: the EPR effect and beyond.
Maeda H
J Control Release; 2012 Dec; 164(2):138-44. PubMed ID: 22595146
[TBL] [Abstract][Full Text] [Related]
14. The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.
Fang J; Nakamura H; Maeda H
Adv Drug Deliv Rev; 2011 Mar; 63(3):136-51. PubMed ID: 20441782
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
Maeda H; Tsukigawa K; Fang J
Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
[TBL] [Abstract][Full Text] [Related]
16. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.
Maeda H
Bioconjug Chem; 2010 May; 21(5):797-802. PubMed ID: 20397686
[TBL] [Abstract][Full Text] [Related]
17. [General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics].
Matsumura Y; Oda T; Maeda H
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):821-9. PubMed ID: 2952066
[TBL] [Abstract][Full Text] [Related]
18. Tumoritropic and lymphotropic principles of macromolecular drugs.
Maeda H; Matsumura Y
Crit Rev Ther Drug Carrier Syst; 1989; 6(3):193-210. PubMed ID: 2692843
[TBL] [Abstract][Full Text] [Related]
19. Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?
Kobayashi H; Watanabe R; Choyke PL
Theranostics; 2013 Dec; 4(1):81-9. PubMed ID: 24396516
[TBL] [Abstract][Full Text] [Related]
20. [Tumor-targeted chemotherapy with lipid contrast medium and macro molecular anticancer agents theoretical considerations and clinical outcome].
Maeda H; Konno T
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):773-82. PubMed ID: 2985005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
